R. van Solingen-Ristea

发表

Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C.

M. Colombo, X. Forns, F. Nevens, 2016, Annals of hepatology.

The effect of single‐ and multiple‐dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects

M. Peeters, T. Kakuda, R. Hoetelmans, 2014, Journal of clinical pharmacology.

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

W. K. Henry, D. Podzamczer, H. Stellbrink, 2021, Open forum infectious diseases.

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

S. Swindells, S. Oka, C. Orkin, 2020, Journal of acquired immune deficiency syndromes.

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

S. Swindells, Kimberly Smith, H. Crauwels, 2021, AIDS (London, England).

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)

S. Swindells, Kimberly Smith, E. Overton, 2021, The Patient - Patient-Centered Outcomes Research.

Pharmacokinetic Interaction between Telaprevir and Methadone

V. Garg, J. Snoeys, P. Verboven, 2013, Antimicrobial Agents and Chemotherapy.

Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Post-Switch to Dolutegravir and Rilpivirine in SWORD-1/-2.

B. Wynne, J. Llibre, R. van Solingen-Ristea, 2022, Journal of acquired immune deficiency syndromes.

Pharmacokinetics and Short‐Term Safety of Etravirine in Combination With Fluconazole or Voriconazole in HIV‐Negative Volunteers

V. Vyncke, T. Kakuda, G. Smedt, 2013, Journal of clinical pharmacology.

885. Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living with HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials

J. Polli, V. Vannappagari, H. Crauwels, 2021, HIV medicine.

Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.

H. Stellbrink, C. Orkin, Kimberly Smith, 2021, The lancet. HIV.

Pharmacokinetics of bound and unbound telaprevir in cirrhotic patients with moderate and severe hepatic impairment

S. Ouwerkerk-Mahadevan, A. Halabi, Indra Aerts, 2015, Journal of clinical pharmacology.

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

C. Orrell, L. Lavreys, T. Kakuda, 2015, AIDS research and treatment.

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.

Kimberly Smith, H. Crauwels, E. Overton, 2021, The lancet. HIV.

Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1

F. Ssali, V. van Eygen, R. van Solingen-Ristea, 2021, Antimicrobial Agents and Chemotherapy.

Single-dose pharmacokinetics of pediatric and adult formulations of etravirine and swallowability of the 200-mg tablet: results from three Phase 1 studies.

V. Vyncke, M. Peeters, T. Kakuda, 2013, International journal of clinical pharmacology and therapeutics.

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.

S. Oka, C. Orkin, Kimberly Smith, 2021, The lancet. HIV.

Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies

P. Cahn, G. Fätkenheuer, L. Ene, 2021, Antiviral therapy.

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

S. Swindells, Kimberly Smith, H. Crauwels, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy, Safety, and Tolerability of Etravirine With and Without Darunavir/Ritonavir or Raltegravir in Treatment-Experienced Patients: Analysis of the Etravirine Early Access Program in the United States

M. Gottlieb, J. Lalezari, J. Gathe, 2010, Journal of Acquired Immune Deficiency Syndromes.

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority t

S. Oka, S. Walmsley, G. di Perri, 2023, The lancet. HIV.

Efficacy, safety, and pharmacokinetics by BMI category in Phase 3/3b cabotegravir + rilpivirine long-acting trials.

H. Crauwels, P. Patel, E. Birmingham, 2023, The Journal of infectious diseases.